Novel Macrolide Compounds Selective PDE4 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors for inflammatory and allergic diseases often exhibit dose-limiting side effects such as emesis and headache, and existing erythromycin derivatives used for chronic treatments may contribute to antibiotic resistance and possess anti-infective activity, which is undesirable for non-bacterial disease treatment.
Innovation Solution
Development of novel macrolide compounds with a five-membered lactone ring fused to the erythromycin scaffold, specifically substituted with certain side chains, that selectively inhibit phosphodiesterase 4 (PDE4) without significant antibacterial activity, offering a distinct structural approach to overcome side effects and resistance issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PDE4 inhibitors are used to treat inflammatory and allergic diseases, then anti-inflammatory efficacy is improved, but dose-limiting side effects such as emesis and headache occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PDE4 inhibitors through specific substitutions at positions 3, 6, and 9 of the macrolactone ring, as well as modifications to the sugar moiety. These structural parameter changes result in compounds with improved side effect profiles while maintaining PDE4 inhibitory activity, thereby resolving the contradiction between efficacy and tolerability.
Solution Approach 2:
The invention creates composite molecular structures by combining a macrolactone core with specific side chains and sugar moieties. This composite approach allows optimization of both the pharmacological activity (PDE4 inhibition) and pharmacokinetic properties (reduced side effects) within a single molecular framework.
2Reliability
If erythromycin derivatives are used for chronic treatment of non-bacterial diseases, then anti-inflammatory activity is achieved, but anti-infective activity causes development of antibiotic-resistant bacteria
Solution Approach 1:
The patent extracts and eliminates the anti-infective property from erythromycin derivatives by modifying the desosamine sugar moiety and introducing specific substitutions that abolish bacterial binding affinity. This allows the compounds to retain anti-inflammatory activity through PDE4 inhibition while removing the harmful anti-infective effect that drives antibiotic resistance.
Solution Approach 2:
The invention applies local quality changes by making specific modifications to particular regions of the molecule (positions 3, 6, and 9 of the macrolactone ring, and the sugar moiety) that selectively eliminate anti-bacterial activity while preserving anti-inflammatory activity. This localized modification strategy resolves the contradiction between therapeutic benefit and harmful side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These macrolide compounds effectively inhibit PDE4, providing a therapeutic option for inflammatory, allergic, and proliferative diseases like COPD, asthma, and cancer without the side effects and resistance concerns of existing treatments.
Implementation Method 1
PDEs are a family of enzymes that inactivate cyclic nucleotides cAMP and cGMP through hydrolysis to AMP and GMP
Data Source
AI summary
The invention relates to macrolide compounds of formula (I),the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.